|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
AstraZeneca |
|---|---|
| Information provided by: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT00680082 |
Purpose
To describe the way statins are used in France in primary care, that is to determine patients profile (particularly CV risk factors), to determine the way statins are initiated by general practitioners, to evaluate aftercare and to assess patients treated by rosuvastatin
| Condition |
|---|
|
Healthy |
| Study Type: | Observational |
| Study Design: | Cohort, Cross-Sectional |
| Official Title: | Observational Usage Study of Statins in Primary Care in France |
| Estimated Enrollment: | 2100 |
| Study Start Date: | February 2008 |
| Estimated Study Completion Date: | March 2009 |
| Groups/Cohorts |
|---|
|
1
Patients to whom a statin was initiated or switched between 3 and 6 months before consultation
|
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Patients recruited by a GP, community sample
Inclusion Criteria:
Contacts and Locations| Contact: AstraZeneca France MC Clinical Study Information | + 33 1 41 29 40 25 | florence.thomas@astrazeneca.com |
Show 25 Study Locations| Principal Investigator: | Francois Morand | Cegedim Strategic Data - Boulogne Billancourt - France |
| Study Chair: | Jean Dallongeville | Institut Pasteur - Inserm U744 - Lille -France |
More Information
| Responsible Party: | AstraZeneca ( Russel Esterline ) |
| Study ID Numbers: | NIS-CFR-CRE-2007/2 |
| Study First Received: | May 15, 2008 |
| Last Updated: | May 16, 2008 |
| ClinicalTrials.gov Identifier: | NCT00680082 |
| Health Authority: | France: Haute Autorité de Santé Transparency Commission |
|
statins rosuvastatin cross sectional study France CV risk factors |
|
Rosuvastatin Healthy |
